CME information and disclosures![toggle arrow icon](https://manus-media.amboss.com/icons/chevron_up.svg)
To see contributor disclosures related to this article, hover over this reference: [1]
Physicians may earn CME/MOC credit by reading information in this article to address a clinical question, and then completing a brief evaluation, in which they will identify their question and report the impact of any information learned on their clinical practice.
AMBOSS designates this Internet point-of-care activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
For answers to questions about AMBOSS CME, including how to redeem CME/MOC credit, see “Tips and Links” at the bottom of this article.
Summary![toggle arrow icon](https://manus-media.amboss.com/icons/chevron_up.svg)
Serum sickness is a type III hypersensitivity reaction that usually develops as a complication of antitoxin or antivenom administration, but can also occur after antibiotic administration and hepatitis B infection. Symptoms typically occur 1–3 weeks after exposure to the offending agent and include fever, rash, and arthralgia. It is diagnosed clinically and treatment consists primarily of removing the offending agent.
Definition![toggle arrow icon](https://manus-media.amboss.com/icons/chevron_up.svg)
Serum sickness is a classic example of a type III hypersensitivity reaction, which usually develops as a complication of antitoxin or antivenom administration.
Etiology![toggle arrow icon](https://manus-media.amboss.com/icons/chevron_up.svg)
- Antivenom or antitoxin containing animal proteins or serum (→ “serum” sickness), such as:
- Medications: most frequently antibiotics (e.g., penicillin, amoxicillin, cefaclor, trimethoprim-sulfamethoxazole) [2]
- Infections: Hepatitis B virus
Pathophysiology![toggle arrow icon](https://manus-media.amboss.com/icons/chevron_up.svg)
Exposure to an antigen (e.g., antivenom, drug) → formation of antibodies → deposition of antibody-antigen complexes in tissue → activation of the complement cascade → tissue damage and systemic inflammation
Clinical features![toggle arrow icon](https://manus-media.amboss.com/icons/chevron_up.svg)
- Fever
- Rash (urticarial or purpuric)
- Arthralgias, myalgia
- Lymphadenopathy
- Hand edema
- Headache, blurred vision
- Abdominal pain, diarrhea, nausea/vomiting
- Mucosal involvement is uncommon
Symptoms appear 1–3 weeks following initial exposure (because antibodies take several days to form) and typically resolve within a few weeks after discontinuation of the offending agent.
Diagnostics![toggle arrow icon](https://manus-media.amboss.com/icons/chevron_up.svg)
- Clinical diagnosis: see “Clinical features.”
- Laboratory studies: Urinalysis may show mild proteinuria.
Differential diagnoses![toggle arrow icon](https://manus-media.amboss.com/icons/chevron_up.svg)
See also “Hypersensitivity reactions.”
Serum sickness-like reaction
- Epidemiology: much more common than actual serum sickness
-
Etiology: similar to that of serum sickness
- Infections (e.g., hepatitis B, rabies)
- Medications that can act as haptens (e.g., allopurinol, cephalosporins, penicillin)
- Pathogenesis: unclear (likely not the result of a type III hypersensitivity reaction)
-
Clinical features
- Similar to classic serum sickness
- May manifest with severe erythema multiforme and arthralgias
The differential diagnoses listed here are not exhaustive.
Treatment![toggle arrow icon](https://manus-media.amboss.com/icons/chevron_up.svg)
- Stop the offending agent.
- Consider pharmacotherapy, e.g.: [2]
- Systemic glucocorticoids
- H1 blockers
- NSAIDs as needed for arthralgias
Prognosis is excellent once the offending drug is stopped or the causative infection has resolved.